Viking Therapeutics Inc (NASDAQ:VKTX) has been given an average rating of “Buy” by the fourteen brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $19.79.
Several research firms have commented on VKTX. Citigroup began coverage on shares of Viking Therapeutics in a report on Monday, July 15th. They set an “outperform” rating on the stock. ValuEngine downgraded shares of Viking Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 16th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Viking Therapeutics in a report on Friday, August 2nd. Stifel Nicolaus began coverage on shares of Viking Therapeutics in a report on Tuesday, June 25th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, CIBC began coverage on shares of Viking Therapeutics in a report on Tuesday, July 16th. They set an “outperform” rating and a $12.00 price objective on the stock.
Institutional investors have recently made changes to their positions in the company. Capital Investment Advisory Services LLC lifted its holdings in shares of Viking Therapeutics by 126.5% in the second quarter. Capital Investment Advisory Services LLC now owns 3,850 shares of the biotechnology company’s stock worth $32,000 after buying an additional 2,150 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Viking Therapeutics in the second quarter worth about $50,000. Wedbush Securities Inc. purchased a new stake in shares of Viking Therapeutics in the second quarter worth about $97,000. BNP Paribas Arbitrage SA purchased a new stake in shares of Viking Therapeutics in the first quarter worth about $126,000. Finally, Hayden Royal LLC purchased a new stake in shares of Viking Therapeutics in the second quarter worth about $111,000. 62.58% of the stock is currently owned by hedge funds and other institutional investors.
VKTX traded down $0.27 during trading on Friday, hitting $7.00. 268,082 shares of the company traded hands, compared to its average volume of 1,051,246. The firm has a market cap of $524.97 million, a P/E ratio of -17.10 and a beta of 2.32. The stock’s fifty day moving average is $7.08 and its 200 day moving average is $8.10. Viking Therapeutics has a one year low of $6.53 and a one year high of $20.85.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). On average, research analysts anticipate that Viking Therapeutics will post -0.46 earnings per share for the current fiscal year.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Further Reading: How to find the components of the quick ratio
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.